08.01.2021 16:31:26
|
Stock Alert: Chimerix Surges 60% On Acquisition Of Oncoceutics
(RTTNews) - Shares of Chimerix, Inc. (CMRX) surged over 60% on Friday morning after the biopharmaceutical company announced acquisition of Oncoceutics to expand pipeline with late-stage oncology program.
CMRX is currently trading at $8.03, up $3.05 or 61.16%, on the Nasdaq.
Chimerix announced that the company has acquired Oncoceutics, a privately held, clinical-stage biotechnology company developing imipridones, a novel class of compounds.
Oncoceutics' lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021.
Chimerix will pay Oncoceutics shareholders $78 million, of which $39 million is payable in Chimerix stock and $39 million in cash. The payment of $39 million in cash is split $25 million at closing and $14 million on the first anniversary of closing.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Chimerix Incmehr Nachrichten
06.11.24 |
Ausblick: Chimerix mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
12.08.24 |
Ausblick: Chimerix informiert über die jüngsten Quartalsergebnisse (finanzen.net) |